154 related articles for article (PubMed ID: 28286235)
1. Aerosol administration increases the efficacy of oseltamivir for the treatment of mice infected with influenza viruses.
Leyva-Grado VH; Palese P
Antiviral Res; 2017 Jun; 142():12-15. PubMed ID: 28286235
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the efficacy of the neuraminidase inhibitor oseltamivir against 2009 pandemic H1N1 influenza virus in ferrets.
Govorkova EA; Marathe BM; Prevost A; Rehg JE; Webster RG
Antiviral Res; 2011 Aug; 91(2):81-8. PubMed ID: 21635924
[TBL] [Abstract][Full Text] [Related]
3. Combinations of oseltamivir and peramivir for the treatment of influenza A (H1N1) virus infections in cell culture and in mice.
Smee DF; Hurst BL; Wong MH; Tarbet EB; Babu YS; Klumpp K; Morrey JD
Antiviral Res; 2010 Oct; 88(1):38-44. PubMed ID: 20633577
[TBL] [Abstract][Full Text] [Related]
4. Treatment of oseltamivir-resistant influenza A (H1N1) virus infections in mice with antiviral agents.
Smee DF; Julander JG; Tarbet EB; Gross M; Nguyen J
Antiviral Res; 2012 Oct; 96(1):13-20. PubMed ID: 22809862
[TBL] [Abstract][Full Text] [Related]
5. Activities of JNJ63623872 and oseltamivir against influenza A H1N1pdm and H3N2 virus infections in mice.
Smee DF; Barnard DL; Jones SM
Antiviral Res; 2016 Dec; 136():45-50. PubMed ID: 27771390
[TBL] [Abstract][Full Text] [Related]
6. The effect of intravenous peramivir, compared with oral oseltamivir, on the outcome of post-influenza pneumococcal pneumonia in mice.
Tanaka A; Nakamura S; Seki M; Iwanaga N; Kajihara T; Kitano M; Homma T; Kurihara S; Imamura Y; Miyazaki T; Izumikawa K; Kakeya H; Yanagihara K; Kohno S
Antivir Ther; 2015; 20(1):11-9. PubMed ID: 24517996
[TBL] [Abstract][Full Text] [Related]
7. Intravenous peramivir inhibits viral replication, and leads to bacterial clearance and prevention of mortality during murine bacterial co-infection caused by influenza A(H1N1)pdm09 virus and Streptococcus pneumoniae.
Onishi M; Kitano M; Taniguchi K; Homma T; Kobayashi M; Yoshinaga T; Naito A; Sato A
Antiviral Res; 2015 May; 117():52-9. PubMed ID: 25752738
[TBL] [Abstract][Full Text] [Related]
8. Combinations of oseltamivir and fibrates prolong the mean survival time of mice infected with the lethal H7N9 influenza virus.
Xu L; Bao L; Li F; Gu S; Lv Q; Yuan J; Xu Y; Zhu H; Deng W; Li Y; Yao Y; Yu P; Gao Z; Qin C
J Gen Virol; 2015 Jan; 96(Pt 1):46-51. PubMed ID: 25274854
[TBL] [Abstract][Full Text] [Related]
9. Effects of TheraMax on influenza virus infections in cell culture and in mice.
Smee DF; Hurst BL; Wong MH
Antivir Chem Chemother; 2011 Jul; 21(6):231-7. PubMed ID: 21730370
[TBL] [Abstract][Full Text] [Related]
10. Emergence of Oseltamivir-Resistant H7N9 Influenza Viruses in Immunosuppressed Cynomolgus Macaques.
Kiso M; Iwatsuki-Horimoto K; Yamayoshi S; Uraki R; Ito M; Nakajima N; Yamada S; Imai M; Kawakami E; Tomita Y; Fukuyama S; Itoh Y; Ogasawara K; Lopes TJS; Watanabe T; Moncla LH; Hasegawa H; Friedrich TC; Neumann G; Kawaoka Y
J Infect Dis; 2017 Sep; 216(5):582-593. PubMed ID: 28931216
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of laninamivir octanoate in mice with advanced inflammation stage caused by infection of highly lethal influenza virus.
Tomozawa T; Hoshino K; Yamashita M; Kubo S
J Infect Chemother; 2019 Aug; 25(8):584-588. PubMed ID: 30935767
[TBL] [Abstract][Full Text] [Related]
12. Activities of oseltamivir and ribavirin used alone and in combination against infections in mice with recent isolates of influenza A (H1N1) and B viruses.
Smee DF; Wong MH; Bailey KW; Sidwell RW
Antivir Chem Chemother; 2006; 17(4):185-92. PubMed ID: 17066897
[TBL] [Abstract][Full Text] [Related]
13. The combination of oseltamivir with azithromycin does not show additional benefits over oseltamivir monotherapy in mice infected with influenza A(H1N1)pdm2009 virus.
Fage C; Pizzorno A; Rhéaume C; Abed Y; Boivin G
J Med Virol; 2017 Dec; 89(12):2239-2243. PubMed ID: 28792077
[TBL] [Abstract][Full Text] [Related]
14. Assessment of Antiviral Properties of Peramivir against H7N9 Avian Influenza Virus in an Experimental Mouse Model.
Farooqui A; Huang L; Wu S; Cai Y; Su M; Lin P; Chen W; Fang X; Zhang L; Liu Y; Zeng T; Paquette SG; Khan A; Kelvin AA; Kelvin DJ
Antimicrob Agents Chemother; 2015 Dec; 59(12):7255-64. PubMed ID: 26369969
[TBL] [Abstract][Full Text] [Related]
15. Emergence of H7N9 Influenza A Virus Resistant to Neuraminidase Inhibitors in Nonhuman Primates.
Itoh Y; Shichinohe S; Nakayama M; Igarashi M; Ishii A; Ishigaki H; Ishida H; Kitagawa N; Sasamura T; Shiohara M; Doi M; Tsuchiya H; Nakamura S; Okamatsu M; Sakoda Y; Kida H; Ogasawara K
Antimicrob Agents Chemother; 2015 Aug; 59(8):4962-73. PubMed ID: 26055368
[TBL] [Abstract][Full Text] [Related]
16. Combinations of L-N
Smee DF; Dagley A; Tarbet EB
Antivir Chem Chemother; 2017 Apr; 25(1):11-17. PubMed ID: 28417640
[TBL] [Abstract][Full Text] [Related]
17. Simvastatin and oseltamivir combination therapy does not improve the effectiveness of oseltamivir alone following highly pathogenic avian H5N1 influenza virus infection in mice.
Belser JA; Szretter KJ; Katz JM; Tumpey TM
Virology; 2013 Apr; 439(1):42-6. PubMed ID: 23453580
[TBL] [Abstract][Full Text] [Related]
18. Low dose oral combination chemoprophylaxis with oseltamivir and amantadine for influenza A virus infections in mice.
Masihi KN; Schweiger B; Finsterbusch T; Hengel H
J Chemother; 2007 Jun; 19(3):295-303. PubMed ID: 17594925
[TBL] [Abstract][Full Text] [Related]
19. Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice.
Ilyushina NA; Hoffmann E; Salomon R; Webster RG; Govorkova EA
Antivir Ther; 2007; 12(3):363-70. PubMed ID: 17591026
[TBL] [Abstract][Full Text] [Related]
20. Antiviral activity of SA-2 against influenza A virus in vitro/vivo and its inhibition of RNA polymerase.
Yu J; Wang D; Jin J; Xu J; Li M; Wang H; Dou J; Zhou C
Antiviral Res; 2016 Mar; 127():68-78. PubMed ID: 26802558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
